There is currently no specific treatment for hepatitis E.
Image Credit: © RUB, Marquard
Scientific Frontline: Extended "At a Glance" Summary: CRISPR-Cas13d System Inhibits Hepatitis E Virus
The Core Concept: A novel antiviral strategy utilizes the CRISPR-Cas13d system to specifically identify, target, and destroy the RNA of the Hepatitis E virus (HEV). This enzymatic approach effectively halts viral replication without causing damage to the infected host cell.
Key Distinction/Mechanism: Unlike the widely recognized CRISPR-Cas9 system, which cleaves DNA, the Cas13d enzyme exclusively targets and cuts RNA. By utilizing specialized CRISPR RNAs (crRNAs), the enzyme is programmed to sever the HEV genome at precise sequences, terminating virus production while keeping host cell viability intact.
Major Frameworks/Components:
- CRISPR-Cas13d Enzyme: An RNA-guided RNA endonuclease functioning as molecular scissors to systematically degrade viral transcripts.
- crRNAs (CRISPR RNAs): Customizable guide molecules that direct the Cas13d enzyme to complementary viral target sites.
- Open Reading Frame 1 (ORF1): A specific genomic sequence within the Hepatitis E virus identified as the most effective target site for inducing a profound reduction in viral particle production.
- Multiplexing Strategy: Bioinformatic modeling demonstrating that a combination of just three to four distinct crRNAs is sufficient to capture and neutralize the vast majority of known HEV variants, bypassing viral escape mechanisms.
Branch of Science: Virology, Molecular Biology, Genetics, Bioinformatics.
Future Application: The framework provides a foundation for developing broad-spectrum, adaptable antiviral therapies capable of countering rapid viral mutation in Hepatitis E and potentially other RNA-based human pathogens.
Why It Matters: Currently, there is no approved, specific therapeutic treatment for Hepatitis E, a virus that causes significant global morbidity and tens of thousands of deaths annually. This CRISPR-based intervention offers a highly specific, adaptable mechanism to inhibit viral propagation where traditional pharmacology currently lacks solutions.
Enzymatic scissors recognize and cut viral RNA but leave the host cell unharmed. This opens up new antiviral strategies against hepatitis E.
Researchers at Ruhr University Bochum have developed a novel antiviral concept: using the CRISPR/Cas13 system, they were able to specifically suppress the replication of the hepatitis E virus in human cells. Hepatitis E is a common cause of acute liver inflammation worldwide, yet effective specific therapies are still lacking. A team at Ruhr University Bochum, Germany, has now demonstrated that the virus can be targeted using an RNA-directed CRISPR system. The results, published on May 4, 2026, in the journal JHEP Reports, open up new perspectives for the development of antiviral strategies.
Blocking Viral Replication
At the center of the study is the CRISPR/Cas13d system, which—unlike the better-known Cas9—cuts RNA rather than DNA. The researchers developed short guide RNAs (crRNAs) that recognize specific sections of the hepatitis E virus. "Our approach uses the ability of Cas13 to specifically recognize and destroy viral RNA," explains Yannick Brüggemann. In cell culture experiments, this led to a significant reduction in viral replication and the production of infectious virus particles.
The crRNAs targeting a region of the viral genome called ORF1 were particularly effective. They significantly reduced both the number of infected cells and viral production, while cell viability remained unaffected. "This shows that we can attack the virus very specifically without harming the cells," says Eike Steinmann.
A Small Combination Is Sufficient
Another focus was identifying as few crRNAs as possible that could still cover many viral variants. Using bioinformatic analyses, the team showed that just three to four different crRNAs are enough to target the majority of known hepatitis E virus variants. This combination could help counteract the rapid adaptability of viruses. "With just a few targeted components, a broad effect can be achieved," says Emely Richter.
Prospects for New Antiviral Strategies
The study provides an important proof of concept for CRISPR-based antiviral approaches against hepatitis E. However, further steps are needed before clinical application—particularly regarding safe and efficient delivery within the body.
Funding: The work was supported by the German Research Foundation and the German Center for Infection Research, among others.
Published in journal: JHEP Reports
Title: Development of a CRISPR-Cas13-based antiviral strategy against hepatitis E virus
Authors: Emely Richter, Mara Klöhn, Maximilian K. Nocke, Marcel Edgar Friedrich, Daniel Todt, Eike Steinmann, and Yannick Brüggemann
Source/Credit: Ruhr-Universität Bochum | Meike Drießen
Reference Number: vi051126_01
.png)
.jpg)